Cargando…

Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial

BACKGROUND: Accelerated hypofractionated radiotherapy can shorten total treatment time and overcome the accelerated repopulation of tumour cells during radiotherapy. This therapeutic approach has demonstrated good efficacy in the treatment of locally advanced non-small-cell lung cancer (NSCLC). Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Qiang, Liu, Yue-E, Ren, Xiao-Cang, Wang, Na, Chen, Xue-Ji, Wang, Dong-Ying, Zong, Jie, Peng, Yu, Guo, Zhi-Jun, Hu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765388/ https://www.ncbi.nlm.nih.gov/pubmed/23957889 http://dx.doi.org/10.1186/1748-717X-8-201

Ejemplares similares

High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study
por: Liu, Yue-E, et al.
Publicado: (2013)

Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial
por: Ren, Xiao-Cang, et al.
Publicado: (2016)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions
por: Ermiş, Ekin, et al.
Publicado: (2015)

Clinical Outcomes of Dose-Escalated Hypofractionated External Beam Radiation Therapy (5 Gy × 5 Fractions) for Spine Metastasis
por: Shin, Jacob Y., et al.
Publicado: (2022)

Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
por: Lee, Tae Hoon, et al.
Publicado: (2022)

A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer
por: Lin, Qiang, et al.
Publicado: (2013)

Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case Report
por: Cho, Jaeho, et al.
Publicado: (2008)

Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2016)

Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
por: Donato, Vittorio, et al.
Publicado: (2013)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
por: Kovarik, Josef, et al.
Publicado: (2022)

Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2022)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Carboplatin/vinorelbine: Worsening of lung adenocarcinoma: case report
Publicado: (2022)

The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer
por: Devlin, Lynsey, et al.
Publicado: (2022)

Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity
por: Kong, Moonkyoo, et al.
Publicado: (2014)

Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis
por: Yao, Lihong, et al.
Publicado: (2020)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon
por: Kim, Hyunjung, et al.
Publicado: (2014)

Clinical audit of dose-escalated radical radiotherapy for advanced cervical carcinoma using a pragmatic protocol (3 fractions of 8 Gy HDR brachytherapy)
por: Goswami, Jyotirup, et al.
Publicado: (2021)

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
por: Zambatis, Charalambos, et al.
Publicado: (1998)

A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer
por: Lee, Sea-Won, et al.
Publicado: (2016)

Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma
por: Songthong, Anussara, et al.
Publicado: (2015)

Randomized Pilot Study of 20 Gy in 5 Fractions versus 27 Gy in 3 Fractions Radiotherapy for Treating Painful Bone Metastases: A Single Institution Experience
por: Sakr, Amr, et al.
Publicado: (2020)

LINC-26. ORAL VINORELBINE IN PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
por: Cappellano, Andréa M, et al.
Publicado: (2020)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer
por: Karasawa, Kumiko, et al.
Publicado: (2013)

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer
por: Bertholet, Jenny, et al.
Publicado: (2019)

Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study
por: Sanguineti, Giuseppe, et al.
Publicado: (2019)

Ultra-Hypofractionated vs. Moderate Fractionated Whole Breast Three Dimensional Conformal Radiotherapy during the COVID-19 Pandemic
por: Ivanov, Olivera, et al.
Publicado: (2022)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
por: Jiang, Huayong, et al.
Publicado: (2021)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Dose escalation by image-guided intensity-modulated radiotherapy leads to an increase in pain relief for spinal metastases: a comparison study with a regimen of 30 Gy in 10 fractions
por: He, Jinlan, et al.
Publicado: (2017)

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
por: Thomson, David, et al.
Publicado: (2012)

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
por: Kerner, Gerald SMA, et al.
Publicado: (2014)

Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial
por: Bourgier, Celine, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4e0dcokg1ttm5ka3aqg968j2rn